Drug Approval | November 02, 2023
NATCO Pharma announces successful completion of USFDA inspection
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
It´s the first trial to demonstrate the benefits of dual pathway inhibition
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Subscribe To Our Newsletter & Stay Updated
